Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of lead hammerhead ribozyme candidates against human rod opsin mRNA for retinal degeneration therapy.

Experimental eye research - 1 May 2009

Abdelmaksoud Heba E, Yau Edwin H, Zuker Michael, Sullivan Jack M

Abstract excerpt

To identify lead candidate allele-independent hammerhead ribozymes (hhRz) for the treatment of autosomal dominant mutations in the human rod opsin (RHO) gene, we tested a series of hhRzs for potential to significantly knockdown human RHO gene expression in a human cell expression system. Multiple computational criteria were used to select target mRNA regions likely to be single stranded and accessible to hhRz...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoviridae
Share to Algorithms
Share to Gene Knockdown Techniques

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genetic Therapy

Share to Genetic Vectors

Share to Retinal Degeneration

Share to RNA, Catalytic

Share to Rod Opsins

Source

Open in PubMed Open full text

Identifiers

PMID: 19094986
DOI: 10.1016/j.exer.2008.11.018
PMCID: PMC3388947

Genes

RHO

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of lead hammerhead ribozyme candidates against human rod opsin mRNA for retinal degeneration therapy.PMID 19094986Read ↗

Design and validation of therapeutic hammerhead ribozymes for autosomal dominant diseases.Semantic proximity Read ↗

Effects of Pathogenic Variations in the Human Rhodopsin Gene (hRHO) on the Predicted Accessibility for a Lead Candidate Ribozyme.Semantic proximity Read ↗

Ribozyme-based therapeutic approaches for autosomal dominant retinitis pigmentosa.Semantic proximity Read ↗

Log-order improved <i>in trans</i> hammerhead ribozyme turnover rates: reevaluating therapeutic space for small catalytic RNAsSemantic proximity Read ↗

RNA therapeutics for retinal diseasesSemantic proximity Read ↗

Mutation-agnostic gene insertion therapy for RHO-associated autosomal dominant retinitis pigmentosa using zinc finger nucleasesSemantic proximity Read ↗

Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa.Semantic proximity Read ↗

An allele-specific hammerhead ribozyme gene therapy for a porcine model of autosomal dominant retinitis pigmentosa.Semantic proximity Read ↗

Allele-specific antisense oligonucleotides for the treatment of BEST1-related dominantly inherited retinal diseases: An in vitro model.Semantic proximity Read ↗

Synthetic Hammerhead Ribozymes as Therapeutic Tools to Control Disease GenesSemantic proximity Read ↗

Applications of antisense oligonucleotides for the treatment of inherited retinal diseases.Semantic proximity Read ↗

A mutation-agnostic and allele-specific ASO strategy demonstrates potent functional rescue and retinal preservation in RHO-linked retinitis pigmentosaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.